NasdaqCM - Nasdaq Real Time Price USD

MEI Pharma, Inc. (MEIP)

Compare

2.7000

0.0000

(0.00%)

At close: December 13 at 4:00:01 PM EST

2.6300

-0.07

(-2.59%)

After hours: December 13 at 5:00:16 PM EST

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

SAN DIEGO, November 12, 2024--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today reported results for its quarter ended September 30, 2024.

Business Wire last month

MEIP
0.00%
MEI Pharma Reports Fiscal Year End 2024 Cash Position

SAN DIEGO, September 19, 2024--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024.

Business Wire 2 months ago

MEIP
0.00%
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

SAN DIEGO, August 12, 2024--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company’s exclusive financial advisor to assist in its previously announced process to review and evaluate strategic alternatives. The Company remains focused on maximizing the value of its assets for its stockholders.

Business Wire 4 months ago

MEIP
0.00%
MEI Pharma to Consider Strategic Alternatives

SAN DIEGO, July 22, 2024--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today announced that its Board of Directors has determined unanimously to begin evaluation of the Company’s strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of its assets for its stockholders. The Company intends to evaluate and engage a financial advisor to assist in this process.

Business Wire 4 months ago

MEIP
0.00%
7 Undervalued Biotech Stocks to Buy for Big-Time Returns

Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price. Of course, the broader healthcare ecosystem offers a compelling narrative for market participants. As the Covid-19 pandemic demonstrated, no matter how advanced we become as a society, a microscopic virus can impose devastation. In order to protect individuals and communities at large, enterprises need a way to address di

InvestorPlace 5 months ago

MDXG

UTHR

MEIP
0.00%
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

SAN DIEGO, May 09, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events.

Business Wire 7 months ago

MEIP
0.00%
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

SAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that the Company’s Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study. Additionall

Business Wire 8 months ago

MEIP
0.00%
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

SAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that 25% of evaluable patients with relapsed metastatic colorectal cancer ("mCRC") in Cohort 1 of the ongoing Phase 1b study evaluating ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation ("OXPHOS"), in combination with bevacizumab (Avastin®) had

Business Wire 8 months ago

MEIP
0.00%
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

SAN DIEGO, April 10, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time.

Business Wire 8 months ago

MEIP
0.00%
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

SAN DIEGO, March 26, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported initiation of enrollment in a 12-patient expansion cohort in the ongoing Phase 1 study evaluating voruciclib, an investigational selective oral cyclin-dependent kinase 9 ("CDK9") inhibitor, in combination with venetoclax (Venclexta®), a B-cell lymphoma 2 ("BCL2") inhibitor,

Business Wire 8 months ago

MEIP
0.00%
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds

In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds. If you want to skip our discussion on the biotech industry, head over to 5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds. Fitch Ratings maintains a Neutral outlook for the global pharmaceutical and biotech industry in […]

Insider Monkey 9 months ago

MEIP
0.00%
BNTX

MGNX
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -13.70% and 100%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks 9 months ago

MEIP
0.00%
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

SAN DIEGO, February 13, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and six months ended December 31, 2023, and highlighted recent corporate events.

Business Wire 9 months ago

MEIP
0.00%
Is MEI Pharma (MEIP) Attractively Priced?

GreenWood Investors LLC, an investment management firm, released its annual 2023 investor letter. A copy of the same can be downloaded here. 2023 was excellent for the fund’s investors, thanks to the collaborative and constructive engagements, which added immense value to the performance. Despite that, the firm is still seeking more challenges to continue to drive […]

Insider Monkey 10 months ago

MEIP
0.00%
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

SAN DIEGO, January 16, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced the design of the ongoing Phase 1b study of the mitochondrial oxidative phosphorylation (OXPHOS) inhibitor ME-344 in combination with bevacizumab (Avastin®) in refractory metastatic colorectal cancer patients will be presented during a poster session at the 2024 ASCO Gast

Business Wire 10 months ago

MEIP
0.00%

Performance Overview

Return	MEIP	S&P 500
YTD	-53.45%	+26.86%
1-Year	-58.84%	+30.31%
3-Year	-93.26%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MEI Pharma, Inc. (MEIP)

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

MEI Pharma Reports Fiscal Year End 2024 Cash Position

MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

MEI Pharma to Consider Strategic Alternatives

7 Undervalued Biotech Stocks to Buy for Big-Time Returns

MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds

MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

Is MEI Pharma (MEIP) Attractively Priced?

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

Performance Overview